Clovis Oncology Inc. is gearing up for a commercial launch late this year or in early 2017 of the PARP inhibitor rucaparib in ovarian cancer, after terminating development of the next-generation EGFR inhibitor rociletinib.
Clovis initiated a rolling NDA for rucaparib in April for advanced ovarian cancer with BRCA-mutated tumors, including germline and somatic...